Patients who took at least 80 percent of their prescribed blood pressure medicine gained an 11 percent reduction in major cardiovascular events, while patients who took less gained no statistically significant protection at all. The result comes from a pooled analysis of 91,339 people in nine randomized trials, led by Qianqian Yang of the University of Oxford and presented at ESC Congress 2026 in Munich.
The tech news worth your time: 400,000+ professionals from Google, Apple and OpenAI read Techpresso, a daily email with the most interesting tech news and insights.
We may earn a commission if you sign up.
It is a conference presentation, not a published paper, and its numbers should be read with that in mind. Still, the data come from trial participants whose assignment was randomized, which is the feature that separates it from older work on skipped pills.
Nine trials and an 80 percent adherence line
Each of the nine trials compared a blood pressure treatment with placebo or a less intensive regimen. Yang’s group pooled individual participant data, sorted people into higher adherence (at least 80 percent of assigned treatment) or lower adherence (under 80 percent), and compared outcomes within each trial. The European Society of Cardiology’s press release of August 27, 2026 gives the design, and the ScienceDaily summary repeats it.
Adherence slipped even inside trials, where participants are monitored more closely than ordinary patients. The share with higher adherence fell from 88 percent in the first year to 79 percent by year five. Yang noted that earlier evidence came from observational studies that could be confounded by other factors, which is why she turned to randomized data.
The adherence analysis is a slice of a larger effort. HCPLive reports that the overall meta-analysis covered 115,389 participants from 12 trials, with 15,460 major cardiovascular events and 9,591 deaths over a median follow-up of 4.7 years, and that the adherence comparison drew on 91,339 people from nine of those trials. Among them, mean adherence in the treatment arms was 88 percent at one year and 80 percent at five, with the comparison arms a few points lower.
What lower adherence did to blood pressure and heart events
The gap shows up first in the blood pressure readings. Systolic pressure fell 5.2 mmHg more than comparators in the higher-adherence group, versus 3.0 mmHg in the lower-adherence group. A coverage piece by HCPLive reports the confidence intervals: 5.0 to 5.4 for high adherence and 2.7 to 3.3 for low.
The cardiovascular outcome counted stroke, heart attack, ischemic heart disease, or heart failure leading to hospitalization or death. Higher adherers had a hazard ratio of 0.89, an 11 percent reduction. Lower adherers had a hazard ratio of 1.01, and the interval of 0.92 to 1.10 includes no effect, which is why the result reads as a loss of benefit and not proof of harm. Yang’s summary of the finding was blunt: drugs don’t work in patients who don’t take them. The same pattern held for blood pressure itself, where the lower-adherence group still saw a reduction of 3.0 mmHg but about four-tenths less of the effect seen in the higher-adherence group.
The caveats that come with a conference result
The 80 percent cutoff is a classification choice, adherence measures were harmonized across trials, and the lower-adherence interval is wide. As News-Medical noted, the write-up contains no independent experts. The only outside comment comes from Felix Mahfoud, who chairs the ESC Communication Committee and is not independent of the society’s messaging.
The analysis also cannot say why people stopped. Side effects, cost, forgetfulness and lack of symptoms all plausibly play a role, and the pooled data do not separate them. The authors say stratifying within each trial’s randomization preserves the comparison, but adherence itself is a behavior that develops after assignment, so some patient factors could still be tangled up with it.
Funding came from the British Heart Foundation, and Yang reported scholarship support from the China Scholarship Council and the China Oxford Scholarship Fund. The society notes that the views expressed are the authors’ own and not the ESC’s, a standard line for congress material that also reminds readers the abstract has not been through journal peer review.
Roughly half of patients do not take pills as prescribed
The stakes come from scale. The World Health Organization estimates that 1.4 billion adults aged 30 to 79 had hypertension in 2024, and that about 630 million of them, or 44 percent, are diagnosed and treated while another 600 million do not know they have it. Only about 320 million, or 23 percent, have the condition under control, so a treatment that works only when taken sits inside a system that already misses most patients. The ESC release says roughly half of treated patients do not take medication as directed.
Mahfoud said that for years non-adherence has been neglected as a cause of uncontrolled hypertension, and said that assessing it should become a routine part of care. The researchers point to simpler dosing, combination pills and longer-acting drugs that blunt the effect of a missed dose. The unanswered question is whether those fixes raise adherence enough to restore the 11 percent benefit, something this analysis was not designed to test.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
The tech news worth your time: Subscribe to Techpresso →
We may earn a commission if you sign up.
More from Morning Overview
- Two passengers died at an Ohio toll plaza, and the NTSB now wants the cash lanes shut
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
